quinacrine + capecitabine

Quinacrine + capecitabine is an investigational combination therapy consisting of two small molecule drugs, quinacrine and capecitabine. Quinacrine is an acridine derivative historically used as an antimalarial and has demonstrated anticancer properties through multiple mechanisms, including inhibition of NF-κB signaling and p53 activation. Capecitabine is a prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine antimetabolite that interferes with DNA synthesis in rapidly dividing cells. The combination has been studied in patients with treatment-refractory metastatic colorectal cancer (mCRC), where it showed tolerability at the maximum tolerated dose (capecitabine 1000 mg/m² twice daily on days 1–14; quinacrine 100 mg twice daily on days 1–21 of a 21-day cycle). Early-phase clinical data suggest potential activity in heavily pretreated mCRC patients[1][3].